Australian biotech and precision oncology company, Race Oncology, has announced breakthrough preclinical research that has found its drug Zantrene® is able to protect heart muscle cells from death while improving the killing of breast cancer cells when used in combination with the anthracycline, doxorubicin.
- eTurboNews | Trends | Travel News
http://dlvr.it/SCxnpB
No comments:
Post a Comment